TLR4 and Sepsis: Furthermore, the FDA-approved antidiarrheal drug nifuroxazide improves cardiac structure by suppressing the TLR4/NLRP3 pathway in LPS-induced cardiac inflammation 172, although NLRP3's role in sepsis-induced myocardial injury remains in early investigation.